Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and early-stage development of pharmaceuticals for.

Launch date

1987

Employees

Market cap

Enterprise valuation

€1.5b (Public information from Sep 2024)

San Diego California (HQ)

http://ligand.com

https://twitter.com/ligand_lgnd https://www.linkedin.com/company/ligand-pharmaceuticals/

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	186m	277m	196m	131m	154m	180m	215m
% growth	55 %	49 %	(29 %)	(33 %)	17 %	17 %	19 %
EBITDA	32.0m	117m	8.7m	51.2m	85.9m	140m	168m
% EBITDA margin	17 %	42 %	4 %	39 %	56 %	78 %	78 %
Profit	(3.0m)	57.6m	(33.4m)	52.2m	49.2m	60.6m	87.6m
% profit margin	(2 %)	21 %	(17 %)	40 %	32 %	34 %	41 %
EV / revenue	8.6x	9.3x	5.8x	9.5x	12.6x	10.7x	9.0x
EV / EBITDA	50.0x	22.0x	129.2x	24.3x	22.5x	13.8x	11.5x
R&D budget	59.4m	69.0m	36.1m	24.5m	-	-	-
R&D % of revenue	32 %	25 %	18 %	19 %	-	-	-

Date	Investors	Amount	Round
-	Signet Healthcare Partners InterWest Partners	N/A	-
Jan 1989	Venrock	N/A	Seed
Dec 1994	N/A	N/A	IPO
Aug 2014	N/A	$225m	Post IPO Debt
May 2018*	N/A	$650m	Post IPO Convertible
Mar 2022	N/A	N/A	-
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 10 Austria 2 United Kingdom 1

By Industry

By Round

ACQUISITION 8 EARLY VC 3 DEBT 1 SPINOUT 1 POST IPO DEBT 1 SPAC PRIVATE PLACEMENT 1 POST IPO EQUITY 1

Viking Therapeutics

exited

ACQUISITION by Ligand Pharmaceuticals Sep 2008

ACQUISITION by Ligand Pharmaceuticals Aug 2020

ACQUISITION by Ligand Pharmaceuticals Oct 2017

Metabasis Therapeutics

ACQUISITION by Ligand Pharmaceuticals Oct 2009

ACQUISITION by Ligand Pharmaceuticals Dec 2009

Palvella Therapeutics

exited

Dianomi Therapeutics

APEIRON Biologics

ACQUISITION by Ligand Pharmaceuticals Jul 2024